Abstract: A composition comprising at least the following components: a) at least one olefin-based interpolymer that comprises the following properties: i) a melt index (I2)?30 dg/min or a melt flow rate (MFR)?30 dg/min, b) a tackifier; and wherein the composition has a melt index (I2)?10 g/10 min.

Abstract: Embodiments of the present disclosure are directed to a polymeric composition comprising the cross-linked reaction product of an ionomer and a silane crosslinking agent. The ionomer may include an E/X/Y polymer where E is an ethylene monomer, X is ?,?-ethylenically unsaturated carboxylic acid comonomer having 3 to 8 carbons, or its ester, and Y is alkyl acrylate or dicarboxylic acid comonomer. The ionomer comprises from 1 to 30 wt. % of X and from 0 to 40 wt. % of Y. At least a portion of the carboxyl groups of X and optionally Y are neutralized with a metal cation. The silane crosslinking agent has a formula Z((CH2)aSi(OR)b)c. Z is a mono-functional reactive group, R is an alkyl group having 1 to 4 carbon atoms or a hydrogen atom, a is from 1 to 4, b is 3, and c is from 1 to 2.

Abstract: A shutter assembly includes at least two first shutter frame strips, at least two second shutter frame strips, and at least two support beams. The first shutter frame strips are detachably provided at a first side of each of the support beams. The second shutter frame strips are detachably provided at a second side of each of the support beams. The first shutter frame strips and the second shutter frame strips are staggered in a length direction of the first support beam. In the present shutter assembly, the first shutter frame strips and the second shutter frame strips are staggered at two sides of each of the support beams. A gap region between two adjacent first shutter frame strips is exactly obstructed by the corresponding second shutter frame strip. A gap region between two adjacent second shutter frame strips is exactly obstructed by the corresponding first shutter frame strip.

Abstract: Disclosed herein are methods, processes and compositions for preparing a compound of formula 8: (8), and formula 18: (18). The methods and processes comprise performing a first allylic oxidation, a protection reaction, a second allylic oxidation, a reduction reaction, performing an acid-catalyzed coupling reaction, a methylation reaction and a deprotection reaction. Disclosed herein are methods, processes and compositions for enantioselectively preparing compounds of formulae 8 and 18. Also disclosed herein are compositions comprising compounds of formulae 8, 18 and/or intermediates and/or starting material thereof.

Abstract: An article is provided and includes (A) a top layer composed of a composition composed of (i) from 70 wt % to 88 wt % of an ethylene-based polymer, and (ii) from 12 wt % to 30 wt % of an oil, based on the total weight of the top layer. The article further includes (B) a bottom layer composed of a textile.

Abstract: The present disclosure provides an article. In an embodiment, the article includes (A) a top layer composed of a composition composed of (i) from 51 wt % to 90 wt % of a propylene-based polymer, and (ii) from 10 wt % to 49 wt % of an ethylene/octene multi-block copolymer having hard segments and soft segments. The ethylene/octene multi-block copolymer has a soft segment melt temperature (SS-Tm) less than 2° C. The article also includes (B) a bottom layer composed of a textile.

Abstract: A split ring seal has: a first circumferential end and a second circumferential end; an inner diameter surface and an outer diameter surface; a first axial end face and a second axial end face. A circumferentially distributed first plurality of open channels are along the first axial end face. A circumferentially distributed second plurality of open channels are along the second axial end face.

Abstract: A split ring seal has: a first circumferential end and a second circumferential end; an inner diameter surface and an outer diameter surface; a first axial end face and a second axial end face. A circumferentially distributed first plurality of open channels are along the first axial end face. A circumferentially distributed second plurality of open channels are along the second axial end face.

Abstract: Disclosed herein are methods, processes and compositions for preparing a compound of formula 8: (8), and formula 18: (18). The methods and processes comprise performing a first allylic oxidation, a protection reaction, a second allylic oxidation, a reduction reaction, performing an acid-catalyzed coupling reaction, a methylation reaction and a deprotection reaction. Disclosed herein are methods, processes and compositions for enantioselectively preparing compounds of formulae 8 and 18. Also disclosed herein are compositions comprising compounds of formulae 8, 18 and/or intermediates and/or starting material thereof.

Abstract: Methods of identifying agents that modulate the interleukin-17 (IL-17) pathway are described. Said methods use detecting a level of granulocyte colony-stimulating factor (G-CSF) in a cell supernatant and/or detecting an expression level of one gene or a panel of genes of a cell treated with an agent. Also described are probes capable of detecting a gene or panel of genes and kits for identifying agents that modulate the IL-17 pathway.

Abstract: Disclosed are a compound containing a fused ring, a use thereof and a pharmaceutical composition containing same. Provided are a compound as shown in formula I-A, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof or a crystal form thereof. The compound can significantly reduce the levels of HBsAg, HBeAg and HBV DNA, and can be used for preparing a drug for treating hepatitis B, and has good market prospects.

Abstract: A transparent injection overmolded structure (100) encapsulating a real botanical matter (70) including at least one first transparent multilayer film member (50), at least one second transparent multilayer film member (60), a real botanical matter (70) disposed and encapsulated between the surface of the first transparent multilayer film member (50) and the surface of the second transparent multilayer film member (60) forming an integral transparent multilayered encapsulation structure (30), a base member (40) for receiving and attaching to the transparent multi-layered encapsulation structure (30), and an injection overmolded transparent plastic member (20) integral with and enveloping the base member (40) and the transparent multilayered encapsulation structure (30).

Abstract: A method of identifying a subject who is likely to be responsive to a treatment comprising an inhibitor of IL1?, or predicting the responsiveness of a subject to a treatment comprising an inhibitor of IL1?, comprising providing a sample from a subject; administering the inhibitor of IL1? to the sample; measuring levels of one or more biomarkers in the sample; and determining the pharmacodynamic or the pharmacokinetic effect of the inhibitor of IL1? based on the levels of the one or more biomarkers.

Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.

Abstract: A method of determining a pharmacodynamics or pharmacokinetic effect of an inhibitor of IL 1? comprising providing a sample from a subject; administering the inhibitor of IL 1? to the sample; measuring levels of one or more biomarkers in the sample; and determining the pharmacodynamic or the pharmacokinetic effect of the inhibitor of IL 1? based on the levels of the one or more biomarkers.

Abstract: Disclosed are a compound containing a fused ring, a use thereof and a pharmaceutical composition containing same. Provided are a compound as shown in formula I-A, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof or a crystal form thereof. The compound can significantly reduce the levels of HBsAg, HBeAg and HBV DNA, and can be used for preparing a drug for treating hepatitis B, and has good market prospects.

Abstract: A method for predicting maintenance of response to IL-23 antibody therapy and treating a patient having psoriasis with extended dosing intervals after measuring at least one indicator from psoriasis patients before and during treatment with an IL-23 antibody is useful in the treatment of psoriasis.

Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g.